Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biohaven Posts Positive Migraine Results, But Investors Are Wary

Executive Summary

Biohaven's stock price fell significantly after it reported positive Phase III results for rimegepant in the acute treatment of migraine, but concerns about differences between the company's Phase II and III data eased as potential benefits over Allergan's competing oral CGRP inhibitor emerged.

You may also be interested in...



Biohaven's Oral Rimegepant Poised To Alter Migraine Market

Clinical data on the US biotech’s oral CGRP antagonist underlines its potential to change the dynamics of the migraine sector.

Keeping Track: US Approvals For Xpovio And Xembify Highlight Short Holiday Week

The latest drug development news and highlights from our US FDA Performance Tracker.

J.P. Morgan Notebook Day 2: Biogen, GSK, Bluebird, Roche, Amgen, Biohaven, Lilly And FDA's Gottlieb

Daily round-up of news and notes from the 2019 J.P. Morgan Healthcare Conference in San Francisco: Biogen may be looking for gene therapy partner, Lilly CEO says Loxo is just the start, GSK plays up its BCMA, Amgen vows to put money into deals, Biohaven readies oral CGRP inhibitor to compete, and Roche talks value-based payments. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel